SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-134363
Filing Date
2021-11-04
Accepted
2021-11-04 16:06:02
Documents
14
Period of Report
2021-11-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2131899d1_8k.htm   iXBRL 8-K 27368
2 EXHIBIT 99.1 tm2131899d1_ex99-1.htm EX-99.1 67933
3 GRAPHIC tm2131899d1_ex99-1img001.jpg GRAPHIC 17906
  Complete submission text file 0001104659-21-134363.txt   305486

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA iova-20211104.xsd EX-101.SCH 3177
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE iova-20211104_lab.xml EX-101.LAB 34594
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE iova-20211104_pre.xml EX-101.PRE 22705
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2131899d1_8k_htm.xml XML 3624
Mailing Address 999 SKYWAY ROAD SUITE 150 SAN CARLOS CA 94070
Business Address 999 SKYWAY ROAD SUITE 150 SAN CARLOS CA 94070 6502607120
IOVANCE BIOTHERAPEUTICS, INC. (Filer) CIK: 0001425205 (see all company filings)

IRS No.: 753254381 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36860 | Film No.: 211379895
SIC: 2836 Biological Products, (No Diagnostic Substances)